Egos has a reduced capacity to predicts GBS prognosis in Northeast Brazil

• Autor(a) principal: Dourado Junior, Mário Emílio Teixeira
• Data de Publicação: 2018
• Outros Autores: Fernandes, Ugor T., Ramos, Eugênio S., Vital, Ana L. F., Urbano, João C. C., Queiroz, José W., Jeronimo, Selma M. B.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/54238; https://onlinelibrary.wiley.com/doi/10.1111/ane.12995
• topic: guillain-barré syndrome; nerve conduction study; neuropathies; peripheral neuropathies; prognosis

Objective: The Erasmus Guillain Barre Outcome Score (EGOS) is a prognostic model that predicts the chance of being able to walk independently at 6 months after Guillain Barré syndrome (GBS). This study was conducted aiming to determine the validity of EGOS in a Brazilian population.Material and Methods: Data collected from GBS patients in Rio Grande do Norte, Brazil, were used to determine the validity of EGOS. GBS disability score was as-sessed in the second week of disease and at 6 months.Results: A total of 206 subjects were studied. The Brazilian patients were younger, with a more severe clinical presentation, with higher percentage of cranial nerve in-volvement and upper respiratory infection. There was no difference relative to sex or presence of anti- gangliosides antibodies. The demyelinating variant was more com-mon (73.9%). However, only 24% of the Brazilians with EGOS 5.5-7 were not able to walk after 6 months, compared to 52% to European Group. Nine patients (3.8%) pre-sented nodopathies, of these four had an EGOS >5, but only one of the latter group was unable to walk after 6 months of GBS.Conclusions: Erasmus Guillain Barre Outcome Score was not a good predictor for the ability to walk after 6 months of GBS in Rio Grande do Norte, Brazil. Differences could be that the Brazilian GBS were younger, or alternatively, it could be due to a different infection profile or in the incidence of nodopathies.